Filing Flows

Filing Flows › Companies › Interpace Biosciences › Cash flow

Interpace Biosciences cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow$41K in Q2 2026 · $4.1M over twelve months

Operating cash flow$98K
Capital spending−$57K
Free cash flow+$41K
Cash / net income0.6×
Cash conversion cycle57 days

Analysis

In Q2 2026, Interpace Biosciences generated $98K of operating cash flow and spent $57K on capital projects, leaving free cash flow of $41K. That is $479K less than in Q2 2025 ($520K).

Over the twelve months to Jun 30, 2026, operating cash flow was $4.5M; the largest uses were capital spending ($353K); the cash balance rose by $2.2M.

Operating cash flow was $98K against net income of $158K — 0.6× profit, less cash than reported earnings, worth checking against working capital. The largest differences: prepaid and other assets −$795K, receivables −$386K, payables +$374K.

Its cash conversion cycle was 57 days (receivables 61 + inventory 27 − payables 31).

Free cash flow

Interpace Biosciences: free cash flow by quarterInterpace Biosciences: free cash flow by quarter$1.6MQ3 2024$1.1MQ4 2024$1.2MQ1 2025$520KQ2 2025$1.8MQ3 2025$2.1MQ4 2025$142KQ1 2026$41KQ2 2026
Operating cash flow less capital spending.
Interpace Biosciences: operating cash flow against capital spendingInterpace Biosciences: operating cash flow against capital spendingOperating cash flowCapital spending$2.1M$522KQ3 2024$1.2M$129KQ4 2024$1.2M$0Q1 2025$520K$0Q2 2025$1.9M$117KQ3 2025$2.1M$38KQ4 2025$283K$141KQ1 2026$98K$57KQ2 2026
Latest (Q2 2026): Operating cash flow $98K, Capital spending $57K.

Capital allocation, year by year

Interpace Biosciences: where the cash came from (up) and went (down), by fiscal yearInterpace Biosciences: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$8.7MFY2021: Net borrowing −$6.4MFY2021: Shares issued $335KFY2021: Asset sales $39KFY2021: Capital spending −$354K$374KFY2021FY2022: Operating cash flow −$7.7MFY2022: Net borrowing $2.0MFY2022: Shares issued $108KFY2022: Capital spending −$322K$2.1MFY2022FY2023: Operating cash flow $3.8MFY2023: Net borrowing −$5.0MFY2023: Capital spending −$470K$3.8MFY2023FY2024: Operating cash flow $4.6MFY2024: Net borrowing −$5.6MFY2024: Capital spending −$876K$4.6MFY2024FY2025: Operating cash flow $5.8MFY2025: Net borrowing −$4.4MFY2025: Capital spending −$356K$5.8MFY2025
Over these 5 years operating cash flow totalled −$2.1M; the largest uses were net borrowing ($21.4M) and operating cash flow ($16.4M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$2.7M
Debtnone
Net cash$2.7M

Interpace Biosciences funds itself: free cash flow was $4.1M over the last twelve months, with $2.7M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Interpace Biosciences: sources (+) and uses (−) of cash, Q2 2026Interpace Biosciences: sources (+) and uses (−) of cash, Q2 2026Operating cash flow$98KCapital spending−$57KCash drawn (+) / kept (−)−$41K
Interpace Biosciences: sources (+) and uses (−) of cash, TTM to Q2 2026Interpace Biosciences: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow$4.5MCash drawn (+) / kept (−)−$2.2MNot reconciled−$1.9MCapital spending−$353K

From profit to cash

Interpace Biosciences: net income to operating cash flow, Q2 2026Interpace Biosciences: net income to operating cash flow, Q2 2026Net income$158KDepreciation & amortization$127KStock-based pay$4KDeferred taxes$62KReceivables−$386KPayables$374KAccrued liabilities$15KPrepaid and other assets−$795KOther liabilities$108KOperating cash flow$98K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 202661273157
Q1 202658302662
Q4 202558323555
Q3 202569293761
Q2 202579253470
Q1 202568263757
Q4 202459253449
Q3 202451263640

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Cash drawn (+) / kept (−)Free cash flow
Q2 2026$98K−$57K—−$41K$41K
Q1 2026$283K−$141K—−$142K$142K
Q4 2025$2.1M−$38K−$1.0M−$1.1M$2.1M
Q3 2025$1.9M−$117K−$900K−$921K$1.8M
Q2 2025$520K—−$1.0M$694K$520K
Q1 2025$1.2M—−$1.5M$265K$1.2M
Q4 2024$1.2M−$129K−$1.5M$652K$1.1M
Q3 2024$2.1M−$522K−$1.5M−$94K$1.6M

Interpace Biosciences: income statement and cash flow

Interpace Biosciences, Q2 2026: revenue $9.1M (-1% year over year), operating margin 3.5%. The chart follows the revenue to costs, profit and cash.

Interpace Biosciences: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.